Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its ATLAS platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Co.'s GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral cells (NPTs). The GEN-011 NPTs are specific for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived, tumor-specific T cell therapy. Co.'s GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The GNCA average annual return since 2014 is shown above.
The Average Annual Return on the GNCA average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GNCA average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GNCA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|